Photocure ASA (PHCUF) has released an update.
Photocure ASA’s partner Asieris Pharmaceuticals has announced successful Phase III trial results for Cevira, a non-surgical treatment for cervical lesions, highlighting significant pathological regression and HPV clearance in patients aged 20-40. The trial demonstrated both safety and efficacy, providing hope for a new therapeutic option against high-grade squamous intraepithelial lesions (HSIL). Further studies are anticipated for other age groups as the new drug application has been accepted by the NMPA.
For further insights into PHCUF stock, check out TipRanks’ Stock Analysis page.
